Joung Young Hee, Park Se Hee, Moon Ki-Beom, Jeon Jae-Heung, Cho Hye-Sun, Kim Hyun-Soon
School of Biological Sciences & Technology, Chonnam National University, Gwangju 61186, Korea.
Molecular Biofarming Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB), Daejeon 34141, Korea.
Int J Mol Sci. 2016 Oct 13;17(10):1715. doi: 10.3390/ijms17101715.
Disease prevention through vaccination is considered to be the greatest contribution to public health over the past century. Every year more than 100 million children are vaccinated with the standard World Health Organization (WHO)-recommended vaccines including hepatitis B (HepB). HepB is the most serious type of liver infection caused by the hepatitis B virus (HBV), however, it can be prevented by currently available recombinant vaccine, which has an excellent record of safety and effectiveness. To date, recombinant vaccines are produced in many systems of bacteria, yeast, insect, and mammalian and plant cells. Among these platforms, the use of plant cells has received considerable attention in terms of intrinsic safety, scalability, and appropriate modification of target proteins. Research groups worldwide have attempted to develop more efficacious plant-derived vaccines for over 30 diseases, most frequently HepB and influenza. More inspiring, approximately 12 plant-made antigens have already been tested in clinical trials, with successful outcomes. In this study, the latest information from the last 10 years on plant-derived antigens, especially hepatitis B surface antigen, approaches are reviewed and breakthroughs regarding the weak points are also discussed.
通过接种疫苗预防疾病被认为是过去一个世纪对公共卫生的最大贡献。每年有超过1亿儿童接种世界卫生组织（WHO）推荐的标准疫苗，包括乙型肝炎（HepB）疫苗。HepB是由乙型肝炎病毒（HBV）引起的最严重的肝脏感染类型，然而，目前可用的重组疫苗可以预防这种疾病，该疫苗具有出色的安全性和有效性记录。迄今为止，重组疫苗在细菌、酵母、昆虫、哺乳动物和植物细胞等多种系统中生产。在这些平台中，植物细胞的使用在内在安全性、可扩展性和目标蛋白的适当修饰方面受到了相当大的关注。全球研究团队已尝试为30多种疾病开发更有效的植物源疫苗，最常见的是HepB和流感疫苗。更令人鼓舞的是，大约12种植物制造的抗原已在临床试验中进行测试，并取得了成功。在本研究中，回顾了过去10年关于植物源抗原，特别是乙型肝炎表面抗原的最新信息，并讨论了针对其弱点的突破。
